Healthcare provider profile · identity verified

Allen David Bott, MD

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology with Special Qualifications in Child Neurology · OAKLAND, CA · NPI 1770577652

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Allen David Bott, MD received $84,647.15 in general payments during 2025 across 126 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 71.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 9 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Caplyta, Ingrezza, Nuplazid, Rexulti, Ubrelvy.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vraylar by this doctor in 2024.

ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuplazid by this doctor in 2024.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Auvelity by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Caplyta by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rexulti by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ingrezza by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$84,647.15

126 reported records · 8 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$60,110.02	71.0%	78	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$23,908.34	28.2%	30	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$262.93	0.3%	9	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$203.48	0.2%	3	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$63.19	0.1%	2	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$52.65	0.1%	2	2025
ACADIA Pharmaceuticals Inc	Unresolved — no canonical attribution shown	$26.75	0.0%	1	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$19.79	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$47,175.00	14
Honoraria	$20,900.00	5
Consulting Fee	$6,937.50	2
Travel and Lodging	$6,061.44	48
Food and Beverage	$3,362.96	54
Education	$210.25	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$60,110.02	78	2025
Source payment records 2025-06-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,497.50 · Open Payments source 2025-08-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-08-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $413.97 · Open Payments source 2025-08-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $244.95 · Open Payments source 2025-08-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.53 · Open Payments source 2025-08-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.03 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,550.00 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $69.57 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $45.00 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.93 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.40 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $41.20 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.82 · Open Payments source 2025-08-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-09-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.20 · Open Payments source 2025-09-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.50 · Open Payments source 2025-09-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.80 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $93.68 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $112.00 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-09-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.00 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $377.96 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $65.70 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $235.00 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $306.75 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $144.19 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.87 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $49.33 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.57 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $120.00 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.70 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.00 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.48 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.70 · Open Payments source 2025-11-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $130.00 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $130.00 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $128.92 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.53 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $117.59 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-11-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $110.16 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $109.87 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $866.97 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $204.06 · Open Payments source 2025-11-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.20 · Open Payments source 2025-11-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $44.17 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.50 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $111.30 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $102.20 · Open Payments source 2025-11-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-11-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-12-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $112.67 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $128.93 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.80 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.50 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $47.90 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $84.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.40 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $69.61 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $92.40 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $63.49 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$23,908.34	30	2025
Source payment records 2025-03-01 · Axsome Therapeutics, Inc. · $20.05 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $34.24 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $49.45 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $74.19 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $93.70 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $110.26 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $24.73 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $24.73 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $303.97 · Open Payments source 2025-03-27 · Axsome Therapeutics, Inc. · $1,650.00 · Open Payments source 2025-03-28 · Axsome Therapeutics, Inc. · $29.74 · Open Payments source 2025-03-28 · Axsome Therapeutics, Inc. · $74.35 · Open Payments source 2025-03-28 · Axsome Therapeutics, Inc. · $90.00 · Open Payments source 2025-03-28 · Axsome Therapeutics, Inc. · $8.00 · Open Payments source 2025-03-28 · Axsome Therapeutics, Inc. · $42.00 · Open Payments source 2025-04-08 · Axsome Therapeutics, Inc. · $9,350.00 · Open Payments source 2025-05-08 · Axsome Therapeutics, Inc. · $2,475.00 · Open Payments source 2025-05-08 · Axsome Therapeutics, Inc. · $3,850.00 · Open Payments source 2025-05-08 · Axsome Therapeutics, Inc. · $116.28 · Open Payments source 2025-05-08 · Axsome Therapeutics, Inc. · $60.74 · Open Payments source 2025-05-08 · Axsome Therapeutics, Inc. · $414.60 · Open Payments source 2025-05-08 · Axsome Therapeutics, Inc. · $72.00 · Open Payments source 2025-05-08 · Axsome Therapeutics, Inc. · $425.53 · Open Payments source 2025-05-08 · Axsome Therapeutics, Inc. · $238.93 · Open Payments source 2025-05-08 · Axsome Therapeutics, Inc. · $28.00 · Open Payments source 2025-08-14 · Axsome Therapeutics, Inc. · $3,575.00 · Open Payments source 2025-08-14 · Axsome Therapeutics, Inc. · $32.44 · Open Payments source 2025-08-14 · Axsome Therapeutics, Inc. · $125.00 · Open Payments source 2025-08-14 · Axsome Therapeutics, Inc. · $395.71 · Open Payments source 2025-08-14 · Axsome Therapeutics, Inc. · $119.70 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$262.93	9	2025
Source payment records 2025-01-09 · Neurocrine BioSciences, Inc. · $15.08 · Open Payments source 2025-02-05 · Neurocrine BioSciences, Inc. · $9.48 · Open Payments source 2025-02-19 · Neurocrine BioSciences, Inc. · $9.70 · Open Payments source 2025-03-01 · Neurocrine BioSciences, Inc. · $136.70 · Open Payments source 2025-04-15 · Neurocrine BioSciences, Inc. · $14.08 · Open Payments source 2025-08-12 · Neurocrine BioSciences, Inc. · $15.09 · Open Payments source 2025-09-09 · Neurocrine BioSciences, Inc. · $33.43 · Open Payments source 2025-11-06 · Neurocrine BioSciences, Inc. · $14.74 · Open Payments source 2025-12-11 · Neurocrine BioSciences, Inc. · $14.63 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$63.19	2	2025
Source payment records 2025-01-14 · E.R. Squibb & Sons, L.L.C. · $27.27 · Open Payments source 2025-01-14 · E.R. Squibb & Sons, L.L.C. · $35.92 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC	$52.65	2	2025
Source payment records 2025-05-14 · Lundbeck LLC · $30.38 · Open Payments source 2025-06-04 · Lundbeck LLC · $22.27 · Open Payments source
NUPLAZID Normalized: nuplazid	Drug	ACADIA Pharmaceuticals Inc	$26.75	1	2025
Source payment records 2025-04-15 · ACADIA Pharmaceuticals Inc · $26.75 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$20.50	1	2025
Source payment records 2025-07-29 · Teva Pharmaceuticals USA, Inc. · $20.50 · Open Payments source
QULIPTA Normalized: qulipta	Drug	ABBVIE INC.	$19.79	1	2025
Source payment records 2025-08-26 · ABBVIE INC. · $19.79 · Open Payments source
UBRELVY Normalized: ubrelvy	Drug	ABBVIE INC.	$19.79	1	2025
Source payment records 2025-08-26 · ABBVIE INC. · $19.79 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Auvelity auvelity	2025	Auvelity	2024	44 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	14 Beneficiary count suppressed	exact normalized	Medicare Part D
INGREZZA ingrezza	2025	Ingrezza	2024	51 Beneficiary count suppressed	exact normalized	Medicare Part D
NUPLAZID nuplazid	2025	Nuplazid	2024	26 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	54	exact normalized	Medicare Part D
UBRELVY ubrelvy	2025	Ubrelvy	2024	17 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	UBRELVY open payments reported associated product	CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530	Ubrelvy · 2024 Exact normalized brand match · 1 Part D row	17	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	31	suppressed by CMS
ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference	2025	NUPLAZID open payments reported associated product	CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852	Nuplazid · 2024 Exact normalized brand match · 1 Part D row	26	suppressed by CMS
Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference	2025	Auvelity open payments reported associated product	CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064	Auvelity · 2024 Exact normalized brand match · 1 Part D row	44	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986	Rexulti · 2024 Exact normalized brand match · 1 Part D row	54	11
Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference	2025	INGREZZA open payments reported associated product	CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729	Ingrezza · 2024 Exact normalized brand match · 1 Part D row	51	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Venlafaxine Hcl Er	Venlafaxine Hcl	203	25
Duloxetine Hcl	Duloxetine Hcl	156	28
Bupropion Xl	Bupropion Hcl	147	42
Trintellix	Vortioxetine Hydrobromide	121	26
Trazodone Hcl	Trazodone Hcl	105	22
Lamotrigine	Lamotrigine	91	18
Escitalopram Oxalate	Escitalopram Oxalate	88	20
Quetiapine Fumarate	Quetiapine Fumarate	87	20
Clonazepam	Clonazepam	83	15
Aripiprazole	Aripiprazole	61	19
Alprazolam	Alprazolam	58	11
Gabapentin	Gabapentin	58	17
Mirtazapine	Mirtazapine	56	12
Rexulti	Brexpiprazole	54	11
Diazepam	Diazepam	51	suppressed
Ingrezza	Valbenazine Tosylate	51	suppressed
Donepezil Hcl	Donepezil Hcl	50	16
Memantine Hcl Er	Memantine Hcl	45	11
Sertraline Hcl	Sertraline Hcl	45	suppressed
Auvelity	Dextromethorphan Hbr/Bupropion	44	suppressed
Vraylar	Cariprazine Hcl	31	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	28	suppressed
Divalproex Sodium Er	Divalproex Sodium	27	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	26	suppressed
Nuplazid	Pimavanserin Tartrate	26	suppressed
Ropinirole Hcl	Ropinirole Hcl	26	suppressed
Ajovy Autoinjector	Fremanezumab-Vfrm	25	suppressed
Buspirone Hcl	Buspirone Hcl	24	suppressed
Liothyronine Sodium	Liothyronine Sodium	24	suppressed
Rytary	Carbidopa/Levodopa	24	suppressed
Dextroamphetamine Sulfate	Dextroamphetamine Sulfate	22	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	22	suppressed
Lorazepam	Lorazepam	21	suppressed
Vilazodone Hcl	Vilazodone Hcl	21	suppressed
Pregabalin	Pregabalin	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Belsomra	Suvorexant	18	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	18	suppressed
Armodafinil	Armodafinil	17	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	17	suppressed
Ubrelvy	Ubrogepant	17	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	15	suppressed
Caplyta	Lumateperone Tosylate	14	suppressed
Asenapine Maleate	Asenapine Maleate	13	suppressed
Emsam	Selegiline	13	suppressed
Lurasidone Hcl	Lurasidone Hcl	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Methylphenidate Er	Methylphenidate Hcl	12	suppressed
Namzaric	Memantine Hcl/Donepezil Hcl	12	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Zaleplon	Zaleplon	12	suppressed
Baclofen	Baclofen	11	suppressed
Clopidogrel	Clopidogrel Bisulfate	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$84,647.15 · 126 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, INGREZZA, NUPLAZID, QULIPTA, REXULTI, UBRELVY	7	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Auvelity play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error